NovaBay Pharmaceuticals to Participate in Two July 2021 Investment Conferences
EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova® for the eye care market and CelleRx® for the beauty market, announces that management will participate at the upcoming investment conferences:
- Ladenburg Thalmann Virtual Healthcare Conference being held July 13-14. Management will present a company overview on July 14 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). A webcast of the presentation will be available on the NovaBay website.
- A.G.P.’s Virtual MedTech Summer Conference featuring one-on-one investor meetings on July 29.
“We are addressing extremely large markets with our two differentiated products, Avenova and CelleRx, and look forward to sharing details of our growth strategy at these conferences,” said Justin Hall, CEO of NovaBay Pharmaceuticals. “We have set record Avenova unit sales for the past three consecutive quarters, while barely tapping the dry eye market we estimate at 16 million Americans. We also launched our breakthrough product CelleRx late last year, bringing a new level of clinical research and innovation to the beauty category. We are currently rolling out new, sophisticated media campaigns for both Avenova and CelleRx aimed at attracting new customers and encouraging repeat usage.”
“We are also actively evaluating opportunities to support profitable growth through acquisition or licensing of ophthalmic and skincare products,” he added. “Our experienced commercial organization, balance sheet and established industry relationships all give us confidence that we are positioned to pursue new sources of revenue in order to increase shareholder value.”
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on high-quality, differentiated, anti-infective consumer products: Avenova®, the premier antimicrobial lid and lash spray, CelleRx® Clinical Reset™, a breakthrough product in the beauty category, and NeutroPhase® Skin and Wound Cleanser for wound healing. NovaBay’s products are formulated with its patented, pure, stable, pharmaceutical-grade hypochlorous acid that replicates the antimicrobial chemicals used by white blood cells to fight infection. NovaBay’s hypochlorous acid products do not cause stinging or irritation, are non-toxic and non-sensitizing, making them completely safe for regular use. Avenova is the only commercial hypochlorous acid lid and lash spray product clinically proven to reduce bacterial load on ocular skin surfaces, thus effectively addressing the underlying cause of bacterial dry eye.
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of NovaBay Pharmaceuticals, Inc. This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our current product offerings, potential future product offerings, and any future revenue that may result from selling these products, as well as generally the Company’s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the size of the potential market for our products, the possibility that the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the Company’s cash needs, the effect on sales and potential reputational damage resulting from decisions or actions taken by regulators, including Warning Letters issued by the FDA, and any other potential regulatory problems that may arise. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
CelleRx Clinical Reset Purchasing Information
For NovaBay CelleRx Clinical Reset purchasing information
Please call 877-CELLERX
View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005029/en/
Source: NovaBay Pharmaceuticals, Inc.
View this news release online at: